Decreasing the risk of Dementia

Pierre Tariot, MD Related Seminars and Products

Dr. Tariot is Board Certified in Internal Medicine and Psychiatry with added qualifications in geriatrics.  He was as a Fellow at the National Institute of Mental Health (NIMH) Intramural Research Program, then served as a faculty member at the University of Rochester Medical Center and, since 2006, he has served as Director of the Banner Alzheimer’s Institute in Phoenix. He is also a Research Professor of Psychiatry at the University of Arizona College of Medicine. His work has focused on care and study of people with and at risk for Alzheimer’s, with emphasis on design and implementation of clinical trials for prevention and treatment, development of biomarkers, characterization and treatment of neuropsychiatric features of dementia, and demonstration of effective dementia care. His clinical efforts have included planning, funding, and implementing several care initiatives for persons with dementia, including a Project ECHO program and “Dementia Care Partners,” a novel program in which unskilled health coaches are trained to support families dealing with dementia in Banner’s primary care clinics. He teaches undergraduates, medical students, residents, and fellows. His experience includes conceiving, funding, and implementing single center and multicenter trials, and serving as Principal Investigator on over 50 clinical trials related to Alzheimer’s and related dementias. He has published over 450 papers on these topics including those regarding studies that have led to FDA approval of new medications. He serves as co-director of the international Alzheimer’s Prevention Initiative (API). This work includes the creation of pre-enrollment registries in Colombia and the US (the Alzheimer’s Prevention Registry and the related GeneMatch program); fluid and imaging biomarker studies; studies of genetic risk and protective factors; development of novel clinical outcomes for preclinical treatment research; the API Autosomal Dominant AD prevention trial of crenezumab in cognitively unimpaired people destined to develop early onset AD in Colombia, launched in 2013; the global API APOE4 homozygote prevention trial (Generation Study 1) launched in 2015 of an active immunotherapy as well as a BACE inhibitor in cognitively unimpaired people at risk for late onset AD; and the global API Generation Study 2, studying a BACE inhibitor in APOE4 carriers: the two trials were known as the API Generation Program. In partnership with Lilly, he and his colleagues help oversee the “Trailblazer 3” Alzheimer’s prevention trial. His research affiliations include the National Institute on Aging (NIA), the NIMH, and the Alzheimer’s Association and he is a Fellow of the American College of Neuropsychopharmacology.